4D Molecular Therapeutics Secures Up to $11M More from CF Foundation to Accelerate 4D-710 Development

4D Molecular Therapeutics Inc. (NASDAQ:FDMT) is one of the hot stocks to buy with huge upside potential. On October 13, 4D Molecular Therapeutics announced that the company secured up to $11 million in additional funding and technical support from the Cystic Fibrosis Foundation to accelerate the development of 4D-710, which is a genetic medicine for cystic fibrosis/CF lung disease.

The commitment was made following a review of the program and clinical data by the CF Foundation’s independent scientific advisors. This latest financial support includes an initial tranche of $7.5 million and closed in October 2025, bringing the CF Foundation’s total committed funding to 4DMT’s CF programs to ~$32 million to date.

The drug has received Rare Pediatric Disease Designation and Orphan Drug Designation from the FDA. CF is a progressive, inherited disease caused by variants in the CFTR gene. It primarily leads to lung disease, which is the leading cause of morbidity and mortality among CF patients, affecting ~40,000 people in the US and ~105,000 people globally. ~1,000 new cases are diagnosed annually in the US. The condition results in impaired lung function, inflammation, and chronic infections due to the inability to clear thickened mucus.

4D Molecular Therapeutics Inc. (NASDAQ:FDMT) is a late-stage biotechnology company that develops adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution, in the Netherlands and the US.

While we acknowledge the potential of FDMT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.